Law360, New York (June 14, 2013, 5:43 PM EDT) -- The Eighth Circuit on Friday tossed litigation targeting brand-name drug makers for harm allegedly caused by generic medicine but took the somewhat unusual step of refusing to shield a generics company from design defect allegations that have often been blocked by the U.S. Supreme Court’s landmark Mensing decision.
As in many similar suits, Arkansas resident Shirley J. Bell claimed that she developed the neurological disorder tardive dyskinesia after using digestion drug metoclopramide, which goes by the trade name Reglan.
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.